Table 17.
Descriptive reports of adverse outcomes leading to withdrawal from the trial
| Author (Sample size (treatment vs. control) | Results | Descriptive reports of adverse outcomes (results continued) |
|---|---|---|
|
Liu et al. [64] (136; 68 vs. 68) |
Control group (0; 0.0% vs. treatment group (1; 1.5%) |
OR: 3.04 (95% CI 0.12–76.06); p ≥ 0.05 Absolute value (range): 0 fewer per 1000 (from 0 fewer to 0 fewer) Adverse reaction from treatment requiring withdrawal from the trial was mild paroxysmal supraventricular tachycardia. |
|
Parle et al. [71] (94; 52 vs. 42) |
Control group (6; 14.3% vs. treatment group (5; 9.6%) |
OR: 0.64 (95% CI 0.18–2.26); p ≥ 0.05 Absolute value (range): 46 fewer per 1000 (from 114 fewer to 131 more) The side effects resulting in withdrawal from the trial were not described. |
|
(60; 35 vs. 25) |
Control group (0; 0.0% vs. treatment group (2; 5.7%) |
OR: 3.81 (95% CI 0.17–82.80); p ≥ 0.05 Absolute value (range): 0 fewer per 1000 (from 0 fewer to 0 fewer) Adverse events requiring withdrawal from the trial included developing “hashitoxicosis” while on levothyroxine therapy and symptomatic tachycardia |
|
Zhao et al. [77] (369; 210 vs. 159) |
Control group (0; 0.0%) vs. treatment group (0; 0.0%) | No withdrawals due to adverse effects were reported in either the control or treatment groups. |